Teleflex Croissance future

Future contrôle des critères 2/6

Teleflex devrait augmenter ses bénéfices et son chiffre d'affaires de 17.9% et de 5.2% par an respectivement. Le BPA devrait croître de de 19.1% par an. Le rendement des capitaux propres devrait être 11.6% dans 3 ans.

Informations clés

17.9%

Taux de croissance des bénéfices

19.1%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	18.2%
Taux de croissance des recettes	5.2%
Rendement futur des capitaux propres	11.6%
Couverture par les analystes	Good
Dernière mise à jour	21 Jun 2024

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

BOVESPA:T1FX34 - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	3,444	615	725	847	9
12/31/2025	3,260	543	633	731	15
12/31/2024	3,089	409	614	635	15
3/31/2024	3,001	296	430	538	N/A
12/31/2023	2,974	358	419	511	N/A
10/1/2023	2,959	405	381	471	N/A
7/2/2023	2,899	369	326	412	N/A
4/2/2023	2,860	363	278	366	N/A
12/31/2022	2,791	363	264	344	N/A
9/25/2022	2,795	412	373	445	N/A
6/26/2022	2,808	510	421	488	N/A
3/27/2022	2,817	488	537	603	N/A
12/31/2021	2,810	485	580	651	N/A
9/26/2021	2,759	434	565	645	N/A
6/27/2021	2,687	351	479	567	N/A
3/28/2021	2,540	280	468	559	N/A
12/31/2020	2,537	336	346	436	N/A
9/27/2020	2,507	367	307	389	N/A
6/28/2020	2,527	479	327	413	N/A
3/29/2020	2,612	551	265	364	N/A
12/31/2019	2,595	462	337	440	N/A
9/29/2019	2,556	442	318	427	N/A
6/30/2019	2,517	269	317	416	N/A
3/31/2019	2,475	183	326	415	N/A
12/31/2018	2,448	196	357	437	N/A
9/30/2018	2,402	66	331	404	N/A
7/1/2018	2,327	89	332	404	N/A
4/1/2018	2,246	170	342	416	N/A
12/31/2017	2,146	155	N/A	420	N/A
10/1/2017	2,065	259	N/A	427	N/A
7/2/2017	1,986	246	N/A	425	N/A
4/2/2017	1,931	227	N/A	432	N/A
12/31/2016	1,868	237	N/A	408	N/A
9/25/2016	1,828	267	N/A	426	N/A
6/26/2016	1,816	262	N/A	373	N/A
3/27/2016	1,795	248	N/A	326	N/A
12/31/2015	1,799	236	N/A	301	N/A
9/27/2015	1,798	197	N/A	255	N/A
6/28/2015	1,808	191	N/A	276	N/A
3/29/2015	1,821	194	N/A	287	N/A
12/31/2014	1,827	190	N/A	287	N/A
9/28/2014	1,802	174	N/A	301	N/A
6/29/2014	1,759	164	N/A	292	N/A
3/30/2014	1,711	159	N/A	264	N/A
12/31/2013	1,685	151	N/A	228	N/A
9/29/2013	1,656	147	N/A	187	N/A
6/30/2013	1,613	125	N/A	160	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de T1FX34 ( 17.9% par an) est supérieure au taux d'épargne ( 9.9% ).

Bénéfices vs marché: Les bénéfices de T1FX34 ( 17.9% par an) devraient croître plus rapidement que le marché BR ( 12.6% par an).

Croissance élevée des bénéfices: Les bénéfices de T1FX34 devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de T1FX34 ( 5.2% par an) devrait croître plus lentement que le marché de BR ( 7.4% par an).

Croissance élevée des revenus: Le chiffre d'affaires de T1FX34 ( 5.2% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de T1FX34 devrait être faible dans 3 ans ( 11.6 %).

Teleflex Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Teleflex Incorporated Revises Earnings Guidance for the Year 2024

Teleflex Incorporated Revises Earnings Guidance for the Full Year 2024

Teleflex Incorporated Raises Earnings Guidance for the Full Year 2024

Teleflex Incorporated Provides Earnings Guidance for the Full Year 2023

Teleflex Incorporated Updates Earnings Guidance for the Year 2023

Teleflex Incorporated Provides Earnings Guidance for the Year 2023

Recent updates

Teleflex Incorporated Revises Earnings Guidance for the Year 2024

Teleflex Incorporated Announces Quarterly Dividend, Payable December 16, 2024

Teleflex Incorporated Announces First Patient Enrolled Barrigel™ Rectal Spacer Trial for Post Radical Prostatectomy Radiation Therapy

Teleflex Incorporated Launches Next-Generation Arrow VPS Rhythm DLX Device and NaviCurve Stylet in Canada

Teleflex Incorporated Announces the Presentation of Data Supporting the Safety and Efficacy of Barrigel Rectal Spacer

Teleflex Incorporated Revises Earnings Guidance for the Full Year 2024

Teleflex Incorporated Expands Intraosseous Vascular Access Portfolio with New Arrow™ EZ-IO™ Intraosseous Access Procedure Tray

Teleflex Incorporated Announces Quarterly Cash Dividend, Payable on June 14, 2024

Teleflex Incorporated Raises Earnings Guidance for the Full Year 2024

Teleflex Incorporated, Annual General Meeting, May 03, 2024

Teleflex Incorporated Announces Quarterly Dividend, Payable on March 15, 2024

Teleflex Incorporated Offers Its Titan SGS Stapler with Staple Line Reinforcement

Teleflex Incorporated Announces First Patient Enrollment in ACCESS-MANTA Registry

Teleflex Incorporated Announces A New Peer-Reviewed Study in the Nature Journal Prostate Cancer and Prostatic Diseases Confirms the Position of the UroLift System as the Gold Standard in Minimally Invasive Surgical Treatment

Teleflex Incorporated Provides Earnings Guidance for the Full Year 2023

Teleflex Incorporated (NYSE:TFX) acquired Palette Life Sciences for $650 million.

Teleflex Incorporated (NYSE:TFX) acquired Palette Life Sciences for $650 million.

Teleflex Incorporated Announces Extension of Arrow ErgoPack Complete System to Hemodialysis and Large Bore Central Venous Catheters

Teleflex Incorporated Updates Earnings Guidance for the Year 2023

Teleflex Incorporated Receives FDA Clearance for Expanded Indication for QuikClot Control+(TM) Hemostatic Device Usage in Cardiac Surgical Procedures

Teleflex Incorporated (NYSE:TFX) entered into a definitive agreement to acquire Palette Life Sciences AB for $650 million.

Teleflex Incorporated (NYSE:TFX) entered into a definitive agreement to acquire Palette Life Sciences AB from Östersjöstiftelsen, Endowment Arm, Praktikerinvest AB and Recipharm Venture Fund AB for $650 million.

Teleflex Incorporated Receives FDA Clearance for the Wattson Temporary Pacing Guidewire

Teleflex Incorporated Announces the Arrow(R) EZ-Io(R) Needle Is Now FDA Cleared for Use in an MRI Environment

Teleflex Announces Quarterly Dividend, June 15, 2023

Teleflex Incorporated Provides Earnings Guidance for the Year 2023

Teleflex Incorporated Announces Worldwide Recall of Affected Lots of Gibeck Iso-Gard Filter Products

Teleflex Incorporated Revises Earnings Guidance for the Year 2022

Teleflex Incorporated (NYSE:TFX) completed the acquisition of Standard Bariatrics, Inc.

Teleflex Incorporated Launches New Arrow® Pressure Injectable Midline Catheter Portfolio

Teleflex Incorporated (NYSE:TFX) entered into a definitive agreement to acquire Standard Bariatrics, Inc. for $300 million.

Teleflex Incorporated Provides Earnings Guidance for the Full Year of 2022

Teleflex Incorporated (NYSE:TFX) acquired unknown stake in Traverse Vascular Inc.

Teleflex Incorporated Announces First Patient Enrollment in MANTA Ultra Study

Teleflex Launches New Arrow Pressure Injectable Midline Catheter in Australia and New Zealand

Teleflex Incorporated Launches New Arrow Pressure Injectable Midline Catheter in Europe, the Middle East and Africa Region

Teleflex Incorporated Reaffirms Earnings Guidance for the Full Year of 2022

Teleflex Incorporated Announces Regulatory Clearance for Its Urolift® System in China for the Treatment of Benign Prostatic Hyperplasia

Teleflex Announces Health Canada Approval of MANTA® Vascular Closure Device

Teleflex Incorporated Declares Quarterly Cash Dividend, Payable on June 15, 2022

Teleflex Announces the Launch of the UroLift® System in Japan for the Treatment of Benign Prostatic Hyperplasia

Teleflex Incorporated, Annual General Meeting, Apr 29, 2022

Teleflex Incorporated Announces Board Changes

Teleflex Incorporated Declares Quarterly Cash Dividend, Payable March 15, 2022

Teleflex Receives FDA Clearance for Expanded Indication for Specialty Catheter and Coronary Guidewire Use in CTO PCI Procedures

Teleflex Announces Large-Scale Analysis of Real-World Healthcare Claims Data for Enlarged Prostate Procedures At the American Urological Association 2021 Annual Meeting

Teleflex Unveils the UroLift Advanced Tissue Control System and the UroLift 2 System

Teleflex Incorporated Announces New Study Provides Insights into the Biocompatibility and Durability of the UroLiftSystem in Improving Benign Prostatic Hyperplasia Symptoms

Medline Industries, Inc. completed the acquisition of Certain product lines of global respiratory product portfolio of Teleflex Incorporated.

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance